Thursday, November 11, 2021 9:07:43 AM
Nov. 10, 2021
With the biggest ever intraday gain, Unity Biotechnology (UBX +30.0%) is trading near a two-month high after the company reported its Q3 2021 financials and provided business updates.
The highlights of the earnings release include upcoming milestones from biotech’s clinical studies on UBX1325 for patients with wet age-related macular degeneration (AMD).
In H1 2022, Unity (NASDAQ:UBX) expects to begin a Phase 2 proof of concept study for UBX1325 in AMD. The 12-week safety and efficacy data are expected in H2 2022.
Meanwhile, 12-week data from a Phase 2a proof of concept study for UBX1325 in diabetic macular edema (DME) are expected in H1 2022.
With $88.5M cash, cash equivalents, and marketable securities in hand, Unity (UBX) says its liquidity level is enough to fund operations through Q3 2022.
On Tuesday, the company released 24-week data from its Phase 1 single ascending dose (SAD) safety study for UBX1325 in DME.
The benefit from the treatment measured through best-corrected visual acuity (BCVA) reached a mean gain of 9.5 ETDRS letters for the higher doses with the effect lasting 24 weeks post-therapy, according to the results.
Now Read: Unity Biotechnology EPS beats by $0.09
Recent UBX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:00:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:31:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:30:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:04:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:05:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/11/2023 05:15:29 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/08/2023 09:39:06 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/06/2023 10:25:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 08:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 11:05:08 AM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM